CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop the next generation of targeted small molecule drug candidates for cancer treatment, today announced that the Company presented a poster entitled, “CUDC-305, a novel, synthetic Hsp90 inhibitor with unique pharmacological properties” at the 20th European Organization for Research and Treatment of Cancer (EORTC)- National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium on “Molecular Targets and Cancer Therapeutics” in Geneva, Switzerland.
